Open access · CC-BY
via OpenAlex
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial
Milena Silva, David A. Wacker, Brian E. Driver, Abbey Staugaitis, Laura J. Niedernhofer, Elizabeth L. Schmidt, James L. Kirkland, Tamar Tchkonia, Tamara S. Evans, Carlos Hines Serrano, Steffen Ventz, Joseph S. Koopmeiners, Michael A. Puskarich, The STOP-Sepsis Investigators, Bimaje Akpa
Trials · 2024 · ▲ 17 citations
Cellular senescence
Altered intercellular communication
Senolytics
Human
Randomized controlled trial
Abstract
BACKGROUND: Senescent immune cells exhibit altered gene expression and resistance to apoptosis. The prevalence of these cells increases with age and emerging data implicate senescence(definition)-associated maladaptive signaling as a potential contributor to sepsis and septic shock. The senolytic drug fisetin promotes clearance of senescent cells and is hypothesized to mitigate septic responses to infection. METHODS: We are conducting a multi-center, randomized, double-blinded, adaptive allocation phase 2 clinical trial to assess the efficacy of the senolytic drug fisetin in preventing clinical deterioration of elderly patients diagnosed with sepsis. We intend to enroll and randomize 220 elderly patients (age > 65) with the clinical diagnosis of sepsis to receive either fisetin as a single oral dose of 20 mg/kg, fisetin in two oral doses of 20 mg/kg each spaced 1 day apart, or placebo. The primary outcome will be changed in the composite of cardiovascular, respiratory, and renal sequential organ failure assessment scores at 7 days from enrollment. Secondary outcomes include quantification of senescent CD3 + cells at 7 days, and 28-day assessments of organ failure-free days, days in an intensive care unit, and all-cause mortality. DISCUSSION: This multi-center, randomized, double-blinded trial will assess the efficacy of fisetin in preventing clinical deterioration in elderly patients with sepsis and measure the effects of this drug on the prevalence of senescent immune cells. We intend that the results of this phase 2 trial will inform the design of a larger phase 3 study. TRIAL REGISTRATION: This trial is registered to ClinicalTrials.gov under identifier NCT05758246, first posted on March 7, 2023.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s13063-024-08474-2
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Silva, M., Wacker, D.A., Driver, B.E., Staugaitis, A., Niedernhofer, L.J., Schmidt, E.L., Kirkland, J.L., Tchkonia, T., Evans, T.S., Serrano, C.H., Ventz, S., Koopmeiners, J.S., Puskarich, M.A., Investigators, T.S., Akpa, B., Bhagat, M., Ingraham, N.E., Kesler, S.M., Kubbara, A.F., & Mahan, K. (2024). Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial. <em>Trials</em>. https://doi.org/10.1186/s13063-024-08474-2
Vancouver
Silva M, Wacker DA, Driver BE, Staugaitis A, Niedernhofer LJ, Schmidt EL, et al. Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial. Trials. 2024. doi:10.1186/s13063-024-08474-2.
BibTeX
@article{milena2024Senoly,
title = {Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial},
author = {Milena Silva and David A. Wacker and Brian E. Driver and Abbey Staugaitis and Laura J. Niedernhofer and Elizabeth L. Schmidt and James L. Kirkland and Tamar Tchkonia and Tamara S. Evans and Carlos Hines Serrano and Steffen Ventz and Joseph S. Koopmeiners and Michael A. Puskarich and The STOP-Sepsis Investigators and Bimaje Akpa and Milind Bhagat and Nicholas E. Ingraham and Sarah M. Kesler and Aahd F. Kubbara and Kathleen Mahan and Kathryn M. Pendleton and Ronald A. Reilkoff and Steven Skolasinski and MICHAEL W. THORP},
journal = {Trials},
year = {2024},
doi = {10.1186/s13063-024-08474-2},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Parc de Salut Mar 2018
Open access · US-GOV
Randomized Clinical Trial: Assessment of a Multidisciplinary Intervention by a Cardiologist and Geriatrician After Hospital Admission Due to Heart Failure in Elderly Patients.
Jeff Burns, MD 2019
Open access · US-GOV
Randomized Controlled Pilot Trial Of Dapagliflozin In Alzheimer's Disease
Immunological Reviews 2016
Open access · OA
The immune system's role in sepsis progression, resolution, and long‐term outcome
Hospital Israelita Albert Einstein 2023
Open access · US-GOV
Immune Response and Affective States of Elderly and 50+ Individuals After Intentional and Indirect Contact With Nature: a Randomized Controlled Clinical Trial
Universidad de Almeria 2020
Open access · US-GOV
The Effect of Probiotic Supplementation on Cognitive and Emotional Functions in Healthy Elderly Subjects: a Randomized, Double-blind, Cross-over and Controlled Trial
Aleksandra Stark 2017
Open access · US-GOV